Conference abstract · 30 Oct 2017
Conference abstractPublished 25 Sep 2017
Impact of vinpocetine on the therapeutic effectiveness of L-DOPA using rat model of Parkinson's disease
Al-Azhar University, Egypt
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Parkinson's disease (PD) represents the most common movement disorder which is characterized by progressive degeneration of dopaminergic neurons as well as dysfunction of the basal ganglia. L-DOPA is still the gold standard effective therapy in PD despite the periodic increase of dosage to achieve stable therapeutic effects along with the long-term treatment side effects. Vinpocetine (Vinp) has been used for treatment of cerebrovascular disorders and may be promising as neuroprotective and PD modifier. Objective: The objective of this study is to evaluate and compare the efficacy of Vinp and/or L-DOPA against rotenone-induced PD in rats as well as the possibility of L-DOPA dosage reduction without compromising the therapeutic effectiveness. Methods: Rats were divided to normal group and five rotenone (RT) groups. One of RT (2.5 mg/kg) groups served as control PD model while the others were treated with either L-DOPA (10 or 25 mg/kg), Vinp (6 mg/kg) or both Vinp and L-DOPA (10 mg/kg) all for 19 days. Motor and cognitive performances were assessed using catalepsy, open-field and Y-maze tests. Striatal dopamine, norepinephrine, serotonin and acetylcholinesterase as well as mitochondrial complex I, MDA, SOD, TAC, IL-1β, TNF-α, and caspase-3 expression were measured in addition to histopathological examination of different brain regions. Results: Concurrent treatment with Vinp and/or L-DOPA significantly ameliorated the impairments in locomotor activities and cognition as well as attenuated the depletions in monoamines and mitochondrial complex1 contents. In addition, the elevations in acetylcholinesterase activity, oxidative stress and inflammatory markers as well as caspase 3 expression induced by RT were also decreased. Combination of Vinp with low dose L-DOPA has an equivalent or almost better effect than the higher dose of L-DOPA alone. Conclusion: Vinp has beneficial motor, cognitive, neurochemical effects and represents a promising adjuvant to L-DOPA therapy that can be translated into a serious reduction of its therapeutic doses and consequently reduction of the long-term therapy side effects. Consequently, Vinp could be recommended as a disease-modifying therapy of PD especially when given early with L-DOPA.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 5 Dec 2016
Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease
Conference abstract · 16 Feb 2019
The potential role of propolis on the therapeutic effectiveness of L-dopa during development of parkinsonism in rats
Conference abstract · 18 May 2018
Pre-Clinical Investigation of Combo Drug Containing L-Dopa And Ceftriaxone in Mouse Models Of Parkinson’s Disease
Conference abstract · 3 Sep 2021
The Electroactive Signal for the Tau Peptide- Part 2: Neuromolecular Imaging (NMI): A LIVE Nanotechnology for Alzheimer, Parkinson and Epilepsy Disease: The BRODERICK PROBE� Biosensor Images the Effects of the Pharmaceutical, L-DOPA, in Long-Term Neurodegeneration in Parkinson Subjects
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Azza A Ali”
